Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 86Terminated 23Unknown 17Active not recruiting 6Withdrawn 3Recruiting 3Not yet recruiting 2Enrolling by invitation 1Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Gastrointestinal Stromal Tumors 8Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 2Hematologic Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor Cancer 1Rare Tumor 1Rare Malignant Neoplasm 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Melanoma 1Lymphangioleiomyomatosis 1Leukemia, Myeloid, Chronic-Phase 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Breast Neoplasms 1Blast Crisis 1

Interventions

asciminib 10Cyclophosphamide 9Mycophenolic Acid 7fludarabine 5Whole-Body Irradiation 5nilotinib 4fludarabine phosphate 4Stem Cell Transplantation 4Specimen Handling 4Dasatinib 4olverembatinib 3bosutinib 3Imatinib Mesylate 3Cyclosporine 3venetoclax 2ponatinib 2blinatumomab 2X-Rays 2Thiotepa 2Tacrolimus 2Sirolimus 2Melphalan 2Magnetic Resonance Spectroscopy 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclosporins 2Bone Marrow Transplantation 2Blood Component Removal 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Imatinib Mesylate × Clear all
NCT04877522 2026-05-11

Asciminib Roll-over Study

Novartis

Phase 4 Recruiting
347 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04838041 2025-07-30

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Medical College of Wisconsin

Phase 2 Recruiting
51 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05282108 2025-03-26

CARCML

Hikma Pharmaceuticals LLC

Recruiting
240 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡